Drug Trial Radar · NCT07917039
SYH2072 Tablets in Participants With Primary Aldosteronism
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 13, 2026
Primary completion
Feb 1, 2028
Study completion Jun 4, 2028
Sponsor
- Lead sponsor
- InnovStone Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to explore the efficacy and safety of SYH2072 tablets in Chinese participants with primary aldosteronism (PA) .
Conditions
- Primary Aldosteronism
Interventions
SYH2072 tabletsDrug
SYH2072 tablets administered orally, once daily (QD)
PlaceboDrug
Placebo administered orally, once daily (QD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in seated Systolic Blood Pressure (SBP) at Week 8Time frame: week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Qilu Hospital of Shandong University
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.